Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands.
- DOI
- 10.1007/s40256-025-00749-6
- Published
- 2025 Sep
- Container
- American journal of cardiovascular drugs : drugs, devices, and other interventions
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40256-025-00749-6,
title = {Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands.},
author = {Slob BPH and Postma MJ and Weersma M and Rocca HB and de Jong LA and Boersma C},
year = {2025},
journal = {American journal of cardiovascular drugs : drugs, devices, and other interventions},
doi = {10.1007/s40256-025-00749-6},
url = {https://doi.org/10.1007/s40256-025-00749-6}
}RIS
TY - JOUR TI - Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands. AU - Slob BPH AU - Postma MJ AU - Weersma M AU - Rocca HB AU - de Jong LA AU - Boersma C PY - 2025 JO - American journal of cardiovascular drugs : drugs, devices, and other interventions DO - 10.1007/s40256-025-00749-6 UR - https://doi.org/10.1007/s40256-025-00749-6 ER -
APA
BPH, S., MJ, P., M, W., HB, R., LA, D. J., & C, B. (2025). Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands.. American journal of cardiovascular drugs : drugs, devices, and other interventions. https://doi.org/10.1007/s40256-025-00749-6
Source records
- pubmed · retrieved 2026-09-25T23:42:13.842Z